Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
VERAVAS, INC. maintains 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 5 distinct examiners and 3 distinct art units. This distribution suggests a complex prosecution landscape, requiring the company to manage various technical reviews simultaneously. The involvement of 3 distinct art units indicates that the company's innovations span different sub-specialties within the biotechnology field.
The busiest examiner for the company is JADHAO, SAMADHAN JAISING, who is responsible for 1 pending office action. Since there are multiple pending actions and distinct examiners, each examiner is currently handling a pending matter. This distribution across the distinct examiners means that the company must navigate different examination styles. However, the concentration within the distinct art units may provide technical overlap in the examination process. Practitioners should coordinate efforts to ensure that responses remain consistent across the pending office actions, even as they address the specific requirements of each individual examiner.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
| SVEIVEN, MICHAEL CAMERON | 1 | 36.0% | +49.2% |
| EVANS, CHRISTOPHER RYAN | 1 | 60.9% | +64.3% |
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
| LUSI, ELLIS FOLLETT | 1 | 64.0% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636012 | COMPOSITIONS AND METHODS FOR DETECTING AND DEPLETING SAMPLE INTERFERENCES | EVANS, CHRISTOPHER RYAN | 11d overdue |
| 17917479 | ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE | SVEIVEN, MICHAEL CAMERON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17263667 | METHODS FOR DEPLETION AND ENRICHMENT | LUSI, ELLIS FOLLETT | 25d overdue |
| 17636012 | COMPOSITIONS AND METHODS FOR DETECTING AND DEPLETING SAMPLE INTERFERENCES | EVANS, CHRISTOPHER RYAN | 11d overdue |
| 17199228 | SAMPLE DEPLETION AND ENRICHMENT TO IMPROVE THE QUALITY OF DIAGNOSTIC TEST RESULTS | HAQ, SHAFIQUL | 2d overdue |
| 18041025 | CORONAVIRUS POINT-OF-CARE AGGLUTINATION ASSAY | JADHAO, SAMADHAN JAISING | 70d |
| 17917479 | ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE | SVEIVEN, MICHAEL CAMERON | — |
| Art Unit | Apps |
|---|---|
| 1678 | 2 |
| 1677 | 2 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041025 | CORONAVIRUS POINT-OF-CARE AGGLUTINATION ASSAY | JADHAO, SAMADHAN JAISING | 1672 | §103 | Final Rejection | 70d | Pending | Feb 08, 2023 |
| 17917479 | ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE | SVEIVEN, MICHAEL CAMERON | 1678 | §103§112Other | Non-Final OA | — | Pending | Oct 06, 2022 |
| 17636012 | COMPOSITIONS AND METHODS FOR DETECTING AND DEPLETING SAMPLE INTERFERENCES | EVANS, CHRISTOPHER RYAN | 1677 | §103§112 | Non-Final OA | 11d overdue | Pending | Feb 16, 2022 |
| 17199228 | SAMPLE DEPLETION AND ENRICHMENT TO IMPROVE THE QUALITY OF DIAGNOSTIC TEST RESULTS | HAQ, SHAFIQUL | 1678 | §103 | Non-Final OA | 2d overdue | Pending | Mar 11, 2021 |
| 17263667 | METHODS FOR DEPLETION AND ENRICHMENT | LUSI, ELLIS FOLLETT | 1677 | §103 | Final Rejection | 25d overdue | Pending | Jan 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVERAVAS, INC. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Samadhan Jaising Jadhao has the most, with 1 of VERAVAS, INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
